Epoetin-induced autoimmune pure red cell aplasia

Hematology Journal

Volumn 5, Issue SUPPL. 3, 2004, Pages

  Casadevall, Nicole ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN ANTIBODY; RECOMBINANT ERYTHROPOIETIN;

ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CLINICAL FEATURE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIESIS; FOLLOW UP; HUMAN; IMMUNOGENICITY; PLASMAPHERESIS; POSTMARKETING SURVEILLANCE; PURE RED CELL ANEMIA; RADIOIMMUNOPRECIPITATION; RISK FACTOR; TREATMENT OUTCOME;

ANTIBODY SPECIFICITY; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; CHEMISTRY, PHARMACEUTICAL; DRUG CONTAMINATION; EPOETIN ALFA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; EUROPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; PROGNOSIS; RED-CELL APLASIA, PURE; RISK FACTORS; SORBITOL; TREATMENT OUTCOME;

EID: 4043133064     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200433     Document Type: Article

References (19)

1. Bergrem H, Danielson BG, Eckardt K-U, Kurtz A, Stridsberg M. A case of antierythropoietin antibodies following recombinant human erythropoietin treatment. In: Marcel Dekker (Ed). Erythropoietin: Molecular Physiology and Clinical Application. New York, NY, 1993, pp 266-275.
2. Peces R, de la Torre M, Alcazar R, Urra JM. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 1996; 335: 523-524.
3. Prabhakar SS, Muhlfelder T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol 1997; 47: 331-335.
4. Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 1996; 334: 630-633.
5. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469-475.
6. Eckardt KU, Casadevall N. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant 2003; 18: 865-869.
7. Gershon SK, Luksenburg H, Cote TR, Braun MM. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2002; 346: 469-475.
8. Krantz SB. Pure red-cell aplasia. N Engl J Med 1974; 291: 345-350.
9. Erslev AJ. Pure red cell apalsia. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U (eds). Williams Hematology, 6th edn. McGraw-Hill: New York, 2000, pp 391-398.
10. Van Regenmortel MHV1. Improving the quality of BIACORE based affinity measurements. In: Brown F, Mire-Sluis AR (eds). Immuogenicity of Therapeutic Biological Products, vol 112, Developmental Biology. Karger: Farmington, CT, 2003, pp 141-151.
11. http://www.jnj.com/news:jnj.
12. Quint L, Casadevall N, Giraudier S. Pure red aplasia in patients with refractory anaemia treated with two different recombinant erythropoietins. Br J Haematol 2004; 124: 842.
13. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002; 1: 457-462.
14. Storring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998; 100: 79-89.
15. Skibeli V, Nissen-Lie G, Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood. 2001; 98: 3626-3634.
16. Hermeling S, Schellekens H, Daan JA, Crommelin DJA, Jiskoot W. Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity? Pharmaceut Res 2003; 20: 1903-1907.
17. Kadri Z, Mayeux P, Casadevall N, Chretien S. Patients developing anti-Epo antibodies during rHuEpo treatment do not express a polymorphic variant of Epo. Kidney Int 2004; 65: 1.
18. Weber G, Gross J, Kromminga A, Loew HH, Eckardt KU. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol 2002; 13: 2381-2383.
19. Verhelst D, Rossert J, Casadevall C, Krger A, Eckardt K-U, Macdougall IC for the PRCA Study Group. Treatment of epoetin-induced pure red cell aplasia, in press.